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ProtectionTo investigate essential factors that determine the efﬁcacy of vaccines against lentiviruses, an effective
attenuated equine infectious anemia virus (EIAV) vaccine strain and a proviral derivative of the vaccine were
compared with respect to differences in inducing protective immunity. Although these two strains replicated
equally well in vitro and in vivo, the proviral strain induced signiﬁcantly less protection from disease and
infection caused by viral challenge and signiﬁcantly lower speciﬁc neutralizing capability. These ﬁndings
indicated that the proviral strain had lost the ability to stimulate immune protection compared to the parental
vaccine strain. A further analysis of the envelope gp90 gene variation revealed that compared to the proviral
strain, the vaccine strain displayed a wide sequence diversity in immunogen composition. Thus, we inferred
that the differences in immunogen composition might be the major cause for the failure of the proviral
derivative to elicit the immune protection induced by the parental strain.erinary Biotechnology, Harbin
icultural Sciences,427 Maduan
6.
), sndhr@163.com (R.-X. Shen).
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Equine infectious anemia virus (EIAV) is an equine lentivirus with
a tropism for macrophages (Leroux et al., 2004). The clinical
manifestation of equine infectious anemia (EIA), which is caused by
EIAV infection, can be divided into an acute phase, a chronic phase,
and an asymptomatic phase. The acute and chronic phases exhibit
typical viremia accompanied by a high fever, anemia, thrombocyto-
penia, edema, and weight loss. The infected equines usually enter the
life-long asymptomatic carrier state after 8–12 months. However, the
virus maintains a low level of stable replication in tissues that are
enrichedwithmonocytes (Hammond et al., 1999; Harrold et al., 2000;
Leroux et al., 2004). Stress or immunosuppression can increase the
EIAV replication level in asymptomatic carriers and thus lead to a
recurrence of EIA. Because most EIAV-infected equines become
asymptomatic carriers due to immune control of the infection, EIAV
has become a unique lentivirus model for studies investigating the
immune control of lentivirus infection and its pathogenesis. In
addition, most asymptomatic EIAV-infected horses demonstrate a
signiﬁcant resistance to infection caused by different pathogenic EIAVstains (Craigo et al., 2007; Leroux et al., 2004). This ﬁnding suggests
that the EIAV system can provide a model for studying key immune
factors that are involved in resistance to lentiviral infection, which can
be used for the research and development of preventive lentivirus
vaccines.
In the early 1970s, Shen et al. developed an attenuated EIAV vaccine
(Cohen, 2004; Shen and Wang, 1985). This vaccine strain, EIAVDLV120,
was developed via a series of in vitro passages of the EIAV pathogenic
strain EIAVD510, which was obtained through the in vivo passaging of a
wild type strain, EIAVLN40, in donkeys (Shen et al., 2001, 1979).
EIAVDLV120 was utilized extensively in China between 1975 and 1990
for the vaccination of 61 million equines to control an EIA pandemic.
This large-scale vaccination successfully controlled the spread of EIA in
China, which resulted in the deaths of 40 million equines due to the
disease or to slaughter (cited from “Equine infectious anemia and its
controlling in China”, a document issued by the Chinese Ministry of
Agriculture in 1997, which is written in Chinese and is available by
request fromthecorrespondingauthor). Theseﬁndings indicate that the
EIAV attenuated vaccine can induce immune protection and can be
safely used for vaccination. Thus, an understanding of the mechanism
that underlies the attenuation of virulence and the induction of immune
protection imparted by this vaccine will elucidate the immune
protective mechanism that is responsible for lentivirus infection and
facilitate the development of lentivirus vaccines.
In recent years, because genetic modiﬁcations can be introduced
easily into viral genomes using molecular cloning techniques, this
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other lentiviruses.Manyvaluable clues have been obtained byexploring
the correlation between genomic information and viral characteristics
using these techniques (Cook et al., 2003, 1998; Glenn and Novembre,
2004; Kinomoto et al., 2005; Liang et al., 2006; Shen et al., 2006). To
further understand the mechanism that underlies the attenuation of
virulence and the induction of immune protection caused by the EIAV
vaccine, a molecular clone, pLGFD3, was constructed from EIAVFDDV12, a
ﬁbroblast-adapted strain of EIAVDLV120 (He et al., 2003). Our previous
studies have indicated that the pLGFD3 contains the entire genome of
EIAVFDDV12 (Liang et al., 2006; Shen et al., 2006). This clone was used to
derive a proviral strain, EIAVFDDV3-8.
The goal of the present study was to determinewhether EIAVFDDV3-
8 could elicit a level of protection against a challengewith a virulent viral
strain thatwas similar to that associatedwith its parental vaccine strain,
EIAVFDDV12. Moreover, we evaluated the replication kinetics, gp90
sequence variation, and the elicited neutralizing antibody responses for
both EIAVFDDV3-8 and EIAVFDDV12 and correlated the results with the
protective effects observed in horses that were challenged with the
highly pathogenic EIAVLN40 strain.
Results
EIAVFDDV12 had signiﬁcantly stronger protective effects against a virulent
viral challenge than did EIAVFDDV3-8
To determine whether the proviral derivative EIAVFDDV3-8 elicited a
level of virulence attenuation and immune protection similar to that
associated with the parental vaccine strain EIAVFDDV12, the protection
efﬁcacy against a challengewith a highly pathogenic viruswas examined
in horses that were immunized with either EIAVFDDV12 or EIAVFDDV3-8.
The EIAVFDDV12-immunized group (Group A), the EIAVFDDV3-8-immu-
nized group (Group B), and the mock-vaccinated control group
(Group C) comprised six, seven, and two horses, respectively.
During the six months of monitoring following the vaccine
inoculation, no abnormal increases in rectal temperatures were
detected in either experimental group of horses. Manifestations
related to EIA, such as thrombocytopenia and rectal temperature,
were not observed. The plasma viral load ﬂuctuated between 102 and
106 copies/ml, which is lower than the pathogenic threshold of EIAV.
A viral challenge with the highly pathogenic EIAVLN40 strain was
conducted six months post the vaccination.
During the three-monthmonitoringperiod following challengewith
EIAVLN40, the mock-vaccinated horses C1 and C2 developed acute EIA
two weeks after the challenge and died on days 28 and 30 post-
challenge, respectively. Accompanied by fever, the platelet counts in
these two horses decreased to below 100×103/μl, and the viral loads
increased to over 1×107 RNA copies/ml, thus exhibiting symptoms
typical of acute EIA. In contrast, horses in the EIAVFDDV12-immunized
Group A appeared to be resistant to the viral challenge. During the
monitoring period, only one of the six horses (A2) developed EIA at
40 days after the challenge, which is signiﬁcantly later than that
observed inGroupC. Thehorses in theEIAVFDDV3-8-immunizedGroupB
showed a signiﬁcantly decreased resistance to the EIAVLN40 challenge in
comparison to Group A. Among the seven horses, ﬁve developed typical
EIA. Among these ﬁve horses, B5 had a febrile episode on day 11 after
inoculation and died seven days later. B4manifested EIA approximately
30 days after inoculation, which is later than that observed in Group C,
and this animal died within one week after the onset of disease. B2 and
B6 also clearly manifested EIA after the challenge, but they demon-
strated only one episode of fever during the monitoring period and
survived. B1 also had one fever episode during the monitoring period.
However, themanifestation of EIA symptoms in this animal occurred at
60 days after the viral challenge,whichdemonstrated a signiﬁcantdelay
in comparison to the other unprotected horses. In addition, in the
EIAVFDDV3-8-vaccinated group, B3 and B7 did not show clinicalmanifestations of EIA, which indicated in the achievement of a clinically
protected state following the EIAV challenge. The clinical and virological
characteristics of the horses described above are shown in Fig. 1.
The horses in experimental Groups A and B exhibited various
levels of protection against a challenge with the pathogenic strain, as
compared with the typical manifestations of the disease and the acute
death observed in the control group. As summarized in Table 1, the
efﬁcacy of the protection against EIA induced by EIAVFDDV3-8 was
signiﬁcantly diminished compared to that induced by the parental
vaccine strain EIAVFDDV12.
EIAVFDDV12 induced signiﬁcantly stronger protection from infection than
did EIAVFDDV3-8 after immunosuppression
The study by Craigo et al. (2007) demonstrated that immunosup-
pression induced by dexamethasone could be used to determine the
efﬁcacy of vaccine-induced sterile protection against EIAV infection. In
the present study, the immunosuppression procedure described by
Craigo et al. was employed to determine the sterile protective capacity
of the vaccine in experimental horses. Immunosuppression was
achieved via a daily injection of dexamethasone into the horses,
which did not exhibit typical clinical manifestations of EIA during
3 months after the challenge. The immune response of the horses was
conﬁrmed as markedly inhibited according to the delayed-type
hypersensitivity (DTH) test after 10 consecutive days of dexamethasone
injection (data not shown). During immunosuppression, two of the ﬁve
treated horses in Group A (A4 and A5) displayed clinical manifestations
of EIA. One of the two clinically protected horses in Group B, B7, also
developed symptoms of EIA (Fig. 1). Gp90 sequences were ampliﬁed
from blood samples of these horses by RT-PCR on day 10 post-injection
during transient immunosuppression, and analyzed for the effect on the
infection of challenge virus based on phylogenetic analysis and the
sequence alignment with the reference sequences of EIAVFDDV12,
EIAVFDDV3-8 and EIAVLN40. The results suggest that the predominant
sequences in horseswith EIAwere all EIAVLN40-like sequences, whereas
those in horseswithout clinicalmanifestations of EIA in Group A (A1, A3
and A6) were still vaccine-like sequences (Fig. 2; the sequence data in
this ﬁgure are presented as Supplementary materials in S-Fig. 1). In
addition, the B3 horse did not display fever symptoms after immuno-
suppression, although it exhibited a moderate decrease in platelet
counts and an increased viral load. Therefore, it did not reach the EIA
onset threshold. An additional sequence analysis revealed that although
the overall gp90 species in this horse were EIAVLN40-like, some
consensus mutation sites (Liang et al., 2006; Ma et al., 2009; Shen
et al., 2006) were vaccine strain-speciﬁc (S-Fig. 1), which implied that
genetic recombination between the virulent and attenuated strains
occurred in this horse. Therefore, B3 was classiﬁed with the group of
horses that was not protected against infection.
To summarize the protective efﬁcacy observed in immunized
horses that were treated with a transient immunosuppression, three
of the ﬁve horses that were immunizedwith EIAVFDDV12 and protected
from disease were also protected against infection. In contrast, only
two of the seven EIAVFDDV3-8-immunized horses were protected from
disease, and none of them was sterile-immunized to resist infection
with the challenge virus (Table 1). These results indicated that the
proviral derivative was unable to elicit the protective immunity
achieved with its parental vaccine strain EIAVFDDV12.
EIAVFDDV12 had a greater ability to induce neutralizing antibodies than
did EIAVFDDV3-8
Although the effect of neutralizing antibodies on immune
protection against lentivirus remains to be clariﬁed (Barouch and
Korber, 2010; Mascola and Monteﬁori, 2010; Srivastava et al., 2004),
the effect of neutralizing antibodies is an important indicator of the
host immune response, which objectively reﬂects the interactions
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Table 1
Protective efﬁcacy of EIAVFDDV12 and EIAVFDDV3-8.
Trial groups Protected from
disease (%)
Protected from
infection (%)
Mortality
(%)
EIAVFDDV 12-immunized (A) 5/6 (83.3) 3/6 (50.0) 0/6 (0)
EIAVFDDV3-8-immunized (B) 2/7 (28.6) 0/7 (0) 3/7 (42.9)
Mock vaccination (C) 0/2 (0) 0/2 (0) 2/2 (100)
Fig. 2. Phylogenetic analysis of nucleotide sequences in viral species that were isolated
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capacities of sera collected from horses that were immunized with
either EIAVFDDV12 or EIAVFDDV3-8 for six months were examined and
compared.
As shown in Fig. 3, the neutralization experiments showed that all
of the horses in Group A displayed a higher serum neutralization
capacity than did the horses in Group B. In Group A, A1, A3, and A6,
which demonstrated a high neutralization titer, all of the animals
developed protection against infection with the challenge virus
EIAVLN40. A4 and A5, which had relatively low neutralization titers
but exhibited an effective neutralization of 50% that was greater than
the cutoff value, failed to develop such protection. However, an
exception was A2, which despite a high neutralization titer,
demonstrated one episode in which the clinical features of EIA were
manifested following the viral challenge. In comparison with Group A,
the horses in Group B generally had sera with a low neutralization
titer (under the cutoff value), and none of the horses in this group
developed protection against EIAVLN40 infection.
Although the correlation between the level of neutralizing anti-
bodies and immune protection remains unclear based on the neutral-
ization data, especially in the case of horse A2, the results demonstrated
a signiﬁcant difference between EIAVFDDV12 and EIAVFDDV3-8 with
respect to the capacity to induce neutralizing antibodies.from vaccinated horses. Gp90 gene species were ampliﬁed and cloned from EIAVFDDV12-
and EIAVFDDV3-8-immunized horses without showing EIA manifestations after a
challenge with the virulent strain EIAVLN40 and were then subjected to transient
immunosuppression. Three horses (A4, A5 and B7, indicated by *) displayed typical
manifestations of EIA following the successive dexamethasone treatment. In contrast,
three other horses (A1, A3 and A6)were protected against infectionwith EIAVLN40, even
under transient immunosuppression. The gp90 sequences of the vaccine strain
EIAVFDDV12 (AF327878), EIAVFDDV3-8 (GU385361.1) and the challenge strain EIAVLN40
(AF327877), which were registered in GenBank, were included as reference sequences.
Bootstrap values of more than 50% were obtained. Detailed sequence information is
presented in S-Fig. 1 in the Supplemental materials.The in vitro and in vivo replication characteristics of EIAVFDDV12 were
similar to those of EIAVFDDV3-8
The replication characteristics of a virus are closely correlated to its
ability to induce an immune response in the host (Craigo et al., 2005;
Ruprecht, 1999; Whitney and Ruprecht, 2004). Therefore, to explore
the potential differences between these two strains in the induction of
an immune response, the in vivo and in vitro replication character-
istics of EIAVFDDV12 and EIAVFDDV3-8 were assessed.
The in vitro replication characteristics of EIAVFDDV12 and EIAV-
FDDV3-8 were ﬁrst examined by monitoring the replication kinetics of
these two strains in FDD cells, as evaluated by the viral reverse
transcriptase (RT) activity. As shown in Fig. 4A, EIAVFDDV12 and
EIAVFDDV3-8 exhibited similar growth curves in FDD cells. Signiﬁcant
growth was observed from two to four days and peaked between
eight and nine days after inoculation, although signiﬁcant differences
were not observed between the two strains (pN0.05). These results
indicated that EIAVFDDV12 and EIAVFDDV3-8 had similar replication
characteristics in adapted cells in vitro.
The dynamic plasma viral loads in horses that were vaccinated
with either EIAVFDDV12 or EIAVFDDV3-8 were analyzed to compare the
in vivo replication characteristic of these two strains. As shown in
Fig. 4B, the plasma viral loads in both vaccinated groups ﬂuctuatedFig. 1. Clinical and virology proﬁles following EIAVLN40 challenge. Horses vaccinated with ei
8 were numbered A1 to A6 and B1 to B7, respectively. Two mock-vaccinated horses were inj
horses in Groups A, B and C were challenged hypodermically with EIAVLN40. All of the animal
the graph). The platelet counts (■, ﬁrst Y-axis on the right in the graph) and plasma virus lo
challenge and on days during which the rectal temperatures exceeded 39 °C. The horses we
dexamethasone-induced transient immunosuppression. The period of immunosuppressio
following the immunosuppression treatment. The total monitoring time following the cha
plasma viral loads and platelet counts that are diagnostic of febrile episodes of EIA, which wer
ml and reduced platelet counts (b100×103/μl of blood). ⋇: Horse died due to severe EIA. Dbetween 102–106 copies/ml prior to challenge with the virulent
strain; this value was lower than the clinical onset threshold of
EIA. In addition, no signiﬁcant difference was detected in the viral
load between these two groups at all of the time points assessed.
Based on a combination of the in vitro and in vivo dynamic growth
curves, EIAVFDDV12 and EIAVFDDV3-8 displayed similar replication
characteristics.
The gp90 gene of the EIAVFDDV12 and EIAVFDDV3-8 strains exhibited
similar in vivo evolution patterns
In addition to plasma viral loads, the genetic evolution of
EIAVFDDV12 and EIAVFDDV3-8 in hosts was analyzed and compared.
The membrane surface protein gp90 is the major protein involved inther the attenuated EIAV vaccine strain EIAVFDDV12 or its proviral derivative EIAVFDDV3-
ected with α-MEM only and designated as C1 and C2. Six months post-vaccination, the
s were monitored daily, and rectal temperatures were recorded (solid line, left Y-axis in
ads (▲, second Y-axis on the right in the graph) were detected at 30 and 60 days post-
re monitored for up to three months. Those animals without EIA episodes underwent a
n is demarcated by a gray box. Another two weeks of monitoring were performed
llenge was 16 weeks. The dashed line deﬁnes the clinical thresholds for temperature,
e deﬁned as a combination of a fever≥39 °C, high plasma viral loads of≥1×107 copies/
PI: days post-inoculation.
Fig. 3. Comparisons of antibody-neutralizing activity in horses that were vaccinated
with either EIAVFDDV12 or EIAVFDDV3-8. Serum samples from horses in Group A and
Group B were collected on day 180 post-inoculation. The serum dilutions that
neutralized 50% of the input EIAVDLV34 were calculated according to the method
described in Materials and methods. The dotted line (…) indicates the cutoff value
(≥1:10) for valid 50% neutralization titers.
100 J. Ma et al. / Virology 410 (2011) 96–106the EIAV-induced immune response (Ball et al., 1992; Cook et al.,
1995; Howe et al., 2002; Leroux et al., 2001; Zheng et al., 1997) and its
sequence is highly variable. Therefore, the gp90 gene was selected for
analysis of the in vivo evolution of EIAV, and it was examined at ﬁve
time points, i.e., 15, 30, 60, 120, and 180 days post-immunization,
which encompassed the entire period of vaccine-induced immune
maturation. Due to the high variability of the gp90 gene, 5–10 clones
per horse were randomly selected for nucleotide sequencing at each
time point. To compare the gp90 sequences between the Chinese EIAV
attenuated vaccine strains and the parental virulent strain EIAVLN40,
11 consensus mutation sites were identiﬁed (Liang et al., 2006; Ma
et al., 2009; Shen et al., 2006). To avoid the interference of randomFig. 4. Comparison of the replication dynamics in vitro (A) and in vivo (B) between EIAVFDDV
RT activity kit each day until day 10 post-inoculation for either EIAVFDDV12 or EIAVFDDV3-8. B
horses were detected by quantitative RT-PCR at 15, 30, 60, 120, 150 and 180 days post-inocu
two immunized groups. The statistical signiﬁcance (p-values) was calculated using SAS sofmutations, the consensus mutation sites in gp90 were used as markers
to analyze the genetic evolution of EIAVFDDV12 and EIAVFDDV3-8 in vivo.
The data summarized in Table 2 show that EIAVFDDV12 displayed an
increase in reverse mutations of these consensus mutations in gp90
within two to four months after inoculation. A similar result was
observed for the proviral strain EIAVFDDV3-8 (Table 3). Therefore,
EIAVFDDV12 and EIAVFDDV3-8 displayed similar in vivo evolution patterns
of the gp90 gene.
Comparison of gp90 gene diversity in EIAVFDDV12 and EIAVFDDV3-8
Given that gp90 is the most important EIAV protein for the
induction of an immune response and that there was a signiﬁcant
difference in the induction of immune protection between EIAVFDDV12
and EIAVFDDV3-8 despite similar replication levels in vivo, an
extensive analysis and comparison of gp90 gene sequences between
these two strains were conducted.
The gp90 gene was ampliﬁed from EIAVFDDV12 by RT-PCR. The
ampliﬁed products from three independent PCR reactions were
pooled and cloned for sequencing. Forty-ﬁve clones that contained
an integrated open reading frame were randomly selected for further
analyses. In these species, the amino acid sequences of gp90 were ﬁrst
scanned and then subjected to a phylogenetic analysis using the
corresponding sequences of EIAVFDDV3-8 and EIAVLN40 as references.
As shown in Fig. 5A, the gp90 protein sequences in EIAVFDDV12
demonstrated a wide variation. Based on their relative positions in the
phylogenetic tree, fourmajor evolutionary brancheswere classiﬁed and
designated as Clade A to Clade D. These four branches encompassed
most of the analyzed sequences. The average amino acid divergence
among these fourmajor branches varied from2.5%±0.5% to 4.0%±0.7%
(average of 3.0%±0.5%). These data revealed that the Chinese EIAV12 and EIAVFDDV3-8. A, RT activity in the cell culture supernatant was detected using the
, The numbers of plasma viral RNA copies in EIAVFDDV12- and EIAVFDDV3-8-immunized
lation. The numbers of RNA copies at different time points were compared between the
tware, version 8.1.
Table 2
Comparison of consensusmutation sites in deduced gp90 amino acid sequence of the vaccine strain EIAVFDDV12 and its derived viruses sequenced from plasma in vaccinated horses at
different time periods.
EIAV strains and
in vivo species
Consensus mutation sites in gp90 of the vaccine strain
46 98 100 103 189 190 193 236 237 321 410
EIAVLN40 A G K/H H K E S D N K H
EIAVFDDV12 E R Q Y/N/C E K N – K E/N Q
DPI15a E R Q Y/N/C E K N – K E/N Q (H)
12/46b (2)c
DPI60 E R Q (K)
1/56 (1)
Y/N E (K)
3/56 (1)
K (E)
1/56 (1)
N – (D)
24/56 (3)
K (N)
34/56 (4)
E/N Q (H)
25/56 (3)
DPI120 E (A)
20/45 (2)
R (G)
20/45 (2)
Q (H)
20/45 (2)
Y (H)
20/45 (2)
E (K)
20/45 (2)
K (E)
21/45 (3)
N (S)
25/45 (3)
– (D)
20/45 (2)
K (N)
20/45 (2)
E/N (K)
20/45 (2)
Q (H)
20/45 (2)
DPI180 E (A)
8/46 (1)
R (G)
1/46 (1)
Q Y E K N – K E/N Q
a DPI15, DPI60, DPI120 and DPI180 designate 15, 60, 120 and 180 days post-immunization, respectively. Five to ten clones were randomly picked from each experimental horse.
b The rates of reverse mutation in total clones analyzed.
c The number in parentheses following the mutation rate indicates the numbers of horses in which reverse mutation occurred.
101J. Ma et al. / Virology 410 (2011) 96–106attenuated vaccine strain actually comprised a pool of quasispecies that
demonstrated signiﬁcant diversity with respect to the composition of
gp90. Furthermore, the reference gp90 sequence of the proviral
derivative EIAVFDDV3-8 was classiﬁed into Clade A of the quasispecies
according to its location in the phylogenetic tree (Fig. 5A). Detailed
sequence information for the gp90 species presented in Fig. 5A is
provided as Supplementary material in S-Fig. 2.
Themutation rates ofﬁfteen gp90 sequences in EIAVFDDV3-8 derived
from the initial molecular clone pLGFD3 were also investigated. The
results indicated that although a small number of mutations was
present, all of the deduced gp90 amino acid sequences clustered in a
single branch of the phylogenetic tree, and the genetic diversity among
these species was 0.2%±0.01% (Fig. 5B). Furthermore, the mutations in
the EIAVFDDV3-8 gp90 sequences were distributed randomly (data not
shown). The divergence of the gp90 gene sequences among the gp90
clones of EIAVFDDV3-8 and the pLGFD3 plasmid did not exceed 0.4%, and
the homology at the amino acid level exceeded 99.1%. These results
demonstrated that there was no signiﬁcant genetic difference between
EIAVFDDV3-8 and pLGFD3 and that the proviral strain was highly
homologous to the initial molecular clone. Moreover, the gp90 gene
diversity of the EIAVFDDV3-8 was signiﬁcantly lower than its parental
strain EIAVFDDV12 (Fig. 5C).
The heterogeneity between EIAVLN40 and EIAVFDDV12
The average deduced gp90 amino acid sequence difference
between EIAVLN40 and the 45 clones of EIAVFDDV12 presented herein
was approximately 6.0% (6.2%±0.9%) (Fig. 5D). In addition, the gp90
sequences of the viral species that were isolated during four febrile
episodes from a horse that was experimentally infected with a
sublethal dose of the EIAVLN40 were assessed. Differences in the
deduced amino acid sequences between the EIAVLN40 species and theTable 3
Comparison of consensus mutation sites in the deduced gp90 amino acid sequence of the va
vaccinated horses at different time periods.
EIAV strains and
in vivo species
Consensus mutation sites in GP90 of the vaccine strain
46 98 100 103 189
EIAVLN40 A G K//H H K
EIAVFDDV3-8 E R Q Y E
DPI15 E R Q Y E
DPI60 E R (G)
1/46 (1)
Q Y E (K)
1/46 (1)
DPI120 E (A)
15/55 (2)
R (G)
15/55 (2)
Q (H)
15/55 (2)
Y (H)
15/55 (2)
E (K)
15/55 (2)
DPI180 E (A)
5/49 (1)
R (G)
5/49 (1)
Q (H)
5/49 (1)
Y (H)
5/49 (1)
E (K)
5/49 (1)45 sequences of EIAVFDDV12 were greater than 6.0% (6.6%±0.9%)
(Fig. 5D).
Discussion
In the present study, the Chinese EIAV attenuated vaccine strain
EIAVFDDV12 provided a clinical protection of over 80% and a sterile
protection of 50% against a challenge with the virulent strain, which
demonstrated a difference in the sequence of gp90 surface protein of
approximately 6%. These results indicated that EIAVFDDV12 induced
immune protection better than did other previously reported EIAV
vaccines (Cook et al., 2005; Hammond et al., 1999; Issel et al., 1992; Li
et al., 2003; McGuire et al., 2004; Ridgely et al., 2003). However, the
proviral strain EIAVFDDV3-8, which was derived from EIAVFDDV12,
produced a clinical protection of less than 30% (2/7) and failed to
induce sterile protection, which indicated that it failed to elicit the
immunogenicity provided by EIAVFDDV12. Although the genetic
background of EIAVFDDV3-8 originates from the proviral DNA of
EIAVFDDV12, and the cell line used for viral rescue and the current
culture conditions are the same as the growth conditions employed
for EIAVFDDV12, EIAVFDDV3-8 lost the immunogenicity associated with
the parental vaccine strain. An understanding of this phenomenon is
an important step in elucidating the mechanism responsible for the
effective immunogenicity generated by EIAVFDDV12.
Genomic and antigenic variations, as observed in EIAV, are a
distinguishing characteristic of animal and human lentiviruses and
are believed to result from errors generated by the viral reverse
transcriptase (RT) in copying genomic RNA to proviral DNA
(Bakhanashvili and Hizi, 1993; Preston et al., 1988; Roberts et al.,
1988). An alignment of the EIAV sequences revealed a high mutation
rate and considerable diversity within both external and internal viral
proteins (Leroux et al., 2001), especially in the envelope protein. Theccine proviral derivative EIAVFDDV3-8 and its derived viruses sequenced from plasma in
190 193 236 237 321 410
E S D N K H
K N – K E Q
K N – K E Q
K N – (D)
9/46 (2)
K (N)
9/46 (2)
E Q
K (E)
15/55 (2)
N (S)
14/55 (2)
– (D)
25/55 (4)
K (N)
25/5 5(4)
E (K)
14/55 (2)
Q (H)
25/55 (4)
K (E)
5/49 (1)
N (S)
5/49 (1)
– K E Q
Fig. 5. Phylogenetic analysis of the deduced amino acid sequences of gp90 in EIAVFDDV12 and EIAVFDDV3-8. The phylogenetic tree of gp90was generated based on sequences that were
randomly selected from the species that were ampliﬁed by RT-PCR from the genomic RNA of EIAVFDDV12 and EIAVFDDV3-8. A, Phylogenetic analysis of the immunogenic diversity of
EIAVFDDV12. The phylogenetic relationship was calculated based on the gp90 sequences determined for 45 clones of EIAVFDDV12. The gp90 sequences for the EIAVFDDV3-
8 (GU385361.1) and EIAVLN40 (AF327877) strains registered in GenBank were included as references. Four major branches in the phylogenetic tree were marked as Clade A to Clade
D. The gp90 sequence in EIAVFDDV3-8 was located in Clade A. B–C, Comparison of the gp90 genetic diversity between EIAVFDDV12 and EIAVFDDV3-8. The gp90 sequences for ﬁfteen
EIAVFDDV12 and ﬁfteen EIAVFDDV3-8 clones and the EIAVFDDV3-8 reference (GU385361.1, indicated by ●) were included in this analysis. The gp90 variation between EIAVFDDV12 and
EIAVFDDV3-8 were compared (B), and the diversity levels were calculated using Dnsp 4.0 software (C). D, Divergence in the deduced amino acid sequences of gp90 between EIAVLN40
and EIAVFDDV12. The sequences of ﬁve gp90 clones were randomly selected from EIAVLN40 prior to inoculation and during each of four different febrile episodes (designated F1 to F4).
The deduced amino acid sequences for these clones and the reference strain of EIAVFDDV12 were compared. The phylogenetic analysis was performed using the neighbor-joining
method provided in the MEGA 4.0 software.
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the immune system during the replication of EIAV in the host (Craigo
et al., 2006; Howe et al., 2002). However, the attenuation process in
the Chinese EIAV attenuated vaccine EIAVFDDV12 consisted of over 100
passages in cell culture, in which a speciﬁc immune pressure was
clearly absent. In addition, the environment for viral replication in
cultured cells differed from that in the target cells in vivo. Thus, we
speculate that the high mutation frequency of the EIAV genome and
the derived antigenic variations accumulate during in vitro replication
over long durations, and this phenomenon eventually leads to a
signiﬁcant diversity of the genetic composition and immunogenicity
of the attenuated vaccine strain. Moreover, the proviral derivativeEIAVFDDV3-8 was obtained via rescue from a homogeneous genetic
background, and it demonstrated a lower probability of mutation due
to a limited number of rescue passages, which resulted in a signiﬁcant
lower gene diversity in comparison to EIAVFDDV12. Therefore, we
hypothesize that the difference in the genomic composition between
EIAVFDDV12 and EIAVFDDV3-8 results in differences in the induction of
an immune protection based on the following three potential
mechanisms.
First, differences in the genetic backgrounds of the EIAVFDDV12 and
EIAVFDDV3-8 strains may result in different viral loads in the host,
which may further affect the induction of immune protection. Based
on the investigation of an attenuated vaccine of SIV, Whitney and
103J. Ma et al. / Virology 410 (2011) 96–106Ruprecht (2004) proposed the threshold hypothesis, in which the
viral replication level in the host is correlated with the induction of
immune protection. Among the quasispecies of EIAVFDDV12, the
genetic mutations in each speciﬁc species can be variable, which
may result in different replication capabilities. Therefore, the
replication capability of EIAVFDDV3-8, which was derived from a
single species of EIAVFDDV12, might be weaker than that of the vaccine
strain. However, the results obtained from an investigation of the
replication kinetics, especially the in vivo replication dynamics, did
not indicate signiﬁcant differences in the replication capability
between these two strains. Moreover, during in vivo replication, the
appearance of the consensus mutation sites in the gp90 protein,
which is an important component of viral replication and virulence,
was similar in these two strains. These observations do not support
the hypothesis that the two strains produce different results in the
induction of immune responses due to different replication capabil-
ities. It is noteworthy that although some mutations reverted to
virulent strain-speciﬁc residues at consensus mutation sites in the
gp90 sequence in both EIAVFDDV12 and EIAVFDDV3-8, which were
isolated from horses that were immunized for two to four months, an
increase in the plasma viral load was not detected during that time
period. This result suggests that these reverse mutations did not affect
the low-level steady replication of the vaccine strain in the
immunized host. Potential explanations for this phenomenon include
the following:mutations in viral proteins other than gp90, such as Gag
and S2, may play an important role in the attenuation of viral
virulence (Li et al., 2003, 2000; Payne and Fuller, 2010; Shen et al.,
2006); strains with reverse mutations may be suppressed by the
gradual maturation of immune pressure, which maintains low-level
copies of the vaccine strain in the host. In addition, reverse mutations
in the gp90 sequences described above may result from the selection
of a pre-existing low-frequency species that is present in the EIAV
vaccine in the in vivo environment. Our previous study revealed
that gp90-containing species that were present at a frequency of
10% or less of the total species of ampliﬁed fragments were hardly
detectable by the cloning of PCR products. Because similar reverse
mutations were observed in both EIAVFDDV12 and EIAVFDDV3–8, and
the latter strain was derived from a molecular clone, this possibility
is low.
Second, the sequence variation in the gp90 gene in EIAVFDDV12may
lead to the difference in immunogenicity observed among different
species of the vaccine strain. If EIAVFDDV3-8 is derived from a species
that possesses an inferior immunogenicity, it may induce a poor
immune response. An analysis of the gp90 sequence in vitro evolution
(Fig. 5A) indicated that the gp90 sequence in EIAVFDDV3-8 was one of
the major evolutionary branches in the multi-species EIAVFDDV12.
Based on the sequence data for the deduced amino acids, the gp90
sequence variability in EIAVFDDV12 within each clade was low (less
than 1.0%). Although the variation among clades A to D was relatively
high (an average of 3.0%), the vaccine-speciﬁc consensus mutations
and glycosylation sites were the same in almost all of the species
examined, and none of the species in any of these four clades could be
considered predominant based on their frequencies among the
quasispecies of EIAVFDDV12. Therefore, it is unlikely that certain
species in EIAVFDDV12 contributed to the predominant immunogenic-
ity, which was superior to that associated with EIAVFDDV3-8 in the
induction of protective immunity. However, future studies should
be conducted to investigate the presence of predominant species in
EIAVFDDV12 that provide superior protective immunity. This goal
could be achieved by constructing proviral derivatives that contain
gp90 sequences from different clades and comparing the immuno-
genicity and efﬁcacy of these derivatives with respect to immune
protection.
The third possible explanation of the differences in immune
protection induced by EIAVFDDV12 or EIAVFDDV3-8 is that diversity in
the composition of the immunogen correlates with the induction of aneffective immune response against EIAV. The multi-envelope vaccine
strategy has been an important tactic in the recent development of
HIV vaccines (Hurwitz et al., 2008; Korber and Gnanakaran, 2009;
Zhan et al., 2005). This vaccine strategy involves the generation of
immunogen diversity by utilizing differential envelope proteins from
different strains. Preclinical and clinical experiments have suggested
that this type of vaccine has potential advantages in the induction of
immune responses over immunogens with a single envelope protein,
especially because the combinatorial use of diverse immunogens can
result in an expanded spectrum of neutralizing antibodies that are
induced by these vaccines (Cho et al., 2001; Hurwitz et al., 2005; Sealy
et al., 2009; Seaman et al., 2005). The results of the present study
revealed that the average difference in the gp90 amino acid sequences
was 3% among the major quasispecies in the attenuated vaccine
strain. Therefore, from the “polyvalent” perspective, these two
approaches are similar. Based on this similarity, when we cannot
exclude the possibility that dominant immunogens are present in the
mixture of diverse immunogens that comprise EIAVFDDV12 but absent
in EIAVFDDV3-8, we consider the difference in immunogen diversity
between the vaccine stock and the proviral derivative as the primary
contributor to the their different capacities with respect to the
induction of protective immunity. The construction of proviral strains
that carry a number of different envelope genes and a comparison of
the immune effects between combined immunization and single
immunization will aid in verifying the importance of genomic
variation of EIAVFDDV12 in inducing protective immunity.
In conclusion, in the present study, we found that a single proviral
derivative failed to elicit the immunogenicity that was associatedwith
its parental attenuated vaccine strain. Based on the genetic back-
ground, immunogen composition, replication characteristics, and
induction of protective immunity between the two strains, we
inferred that a large reduction of the immunogen diversity was the
major contributor to the failure of the proviral strain to retain the
immunogenicity of its parental attenuated strain. Further studies,
including the construction of multiple proviruses that represent a
diverse immunogen composition of the vaccine stock and a
comparison of the immune effects between combined immunization
and single immunization, will aid in conﬁrming the above proposition
and facilitate the elucidation of the mechanism that underlies the
effective immunogenicity of the Chinese attenuated EIAV vaccine.
Materials and methods
Cell culture and virus strains
Fetal donkey dermal (FDD) cell cultures and horse primary
macrophages were used in the present study. FDD cell cultures
were maintained in Minimal Essential Medium (α-MEM, Gibco, USA)
containing 2 mM L-glutamine, 10% heat-inactivated fetal bovine
serum (Gibco), 100 IU penicillin and 100 μg streptomycin/ml. Equine
monocyte-derived macrophages (eMDM) were prepared as follows.
Brieﬂy, supernatant plasma containing mononuclear cells were
isolated from fresh heparinized horse whole blood following an
incubation at room temperature for 30 min. Following two washes
with Ca2+- and Mg2+-free phosphate-buffered saline (PBS), the cells
were resuspended in macrophage culture medium (MCM), seeded in
a culture ﬂask (25 cm2, Corning, USA) and incubated overnight at
37 °C with 5% CO2. The MCM was RPMI 1640 (Gibco) supplemented
with 40% heat-inactivated fetal bovine serum, 10% heat-inactivated
horse serum (Hyclone, USA), 100 IU penicillin and 100 μg streptomy-
cin/ml, and 4 mM L-glutamine. After 24 h incubation, non-adherent
and loosely adherent cells were removed by two washes with RPMI
1640. The adherent cells were detached with 0.9% NaCl and seeded
into 96-well microplates (Corning) in MCM at 1×105 cells/well.
EIAVFDDV12 was developed by passaging a leukocyte-adapted EIAV
vaccine strain, EIAVDLV120, in FDD cells for 12 generations, as described
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length molecular clone of EIAVFDDV12 and was constructed from the
provirusDNAof EIAVFDDV12 (Heet al., 2003). The proviral derivativewas
generated by transfecting pLGFD3 into FDD cells using Lipofectamine™
2000 (Invitrogen, USA) and passing the rescued virus in FDD cells for
six generations to achieve better adaptation and increased viral
production. This proviral strain was designated EIAVFDDV3-8 and was
registered in GenBank (accession number GU385361.1). EIAVLN40
(GenBank accession number AF327877) was a pathogenic EIAV
strain that caused 100% morbidity and more than 90% mortality in
EIAV-negative horses. This virulent strain was used to challenge
horses that were vaccinated with EIAVFDDV12 and EIAVFDDV3-8. Given
that EIAVLN40 failed to replicate in cultured cells, EIAVDLV34, an
eMDM-adapted successor of EIAVLN40, was used as the indicator virus
in the antibody-neutralization assays. Previous experiments demon-
strated that the EIAVDLV34-mediated pathology was similar to that
induced by EIAVLN40. Furthermore, all of the deduced gp90
glycosylation sites in EIAVLN40 were conserved in EIAVDLV34 (data
not shown).
Experimental subjects, clinical evaluation, and sample collection
Fifteen outbred adult horses of both genders that were found to be
seronegative for EIAV infection were used in this study. All of the
horses underwent a daily clinical monitoring and were maintained as
described previously (Craigo et al., 2007;Montelaro et al., 1996). Daily
rectal temperatures and clinical statuses were recorded. Samples of
whole blood, plasma, and serum were collected from each horse at
regular intervals and on days during which apparent febrile episodes
occurred (N39 °C). The plasma samples were stored at−80 °C for use
in quantitative or qualitative RT-PCR assays to determine the levels
and identity (vaccine or challenge virus) of the plasma viral RNA. The
serum samples were stored at −20 °C for the serological assays. A
complete blood count (CBC) analysis of whole blood was performed
using a QBC Vet Autoreader (IDEXX, USA). Platelet numbers were
monitored weekly and on days during which apparent febrile
episodes occurred. All of the animals were handled according to
protocols that were approved by the Animal Management Committee
of Harbin Veterinary Research Institute.
In addition, one EIAV-negativemarewas inoculated hypodermically
with the lowest lethal dose (approximately 104 TCID50) of EIAVLN40
to monitor the in vivo evolution of this virus. The clinical progression
was recorded for one year after inoculation, and four EIA febrile
episodes were observed within this period. Clinical monitoring and
sampling were performed as described for the other experimental
horses.
Experimental vaccination, viral challenge and immunosuppression
procedures
The experimental horses were randomly divided into three
groups. Six horses in Group A were vaccinated via a hypodermic
injection of 105 TCID50 of EIAVFDDV12, and seven horses in Group B
were inoculated with the same dose of EIAVFDDV3-8. Two horses in
Group C were injectedwith the same volume ofα-MEM and served as
the control for the challenge virus (mock-vaccinated controls). Six
months post-vaccination, the horses in groups A, B and C were
challenged hypodermically with ten times the lowest lethal dose
(approximately 105 TCID50) of EIAVLN40. These horses were moni-
tored daily for clinical symptoms of EIA, and blood samples were
drawn at regular intervals to assay the platelet count viral replication,
and neutralizing antibody responses. The horses were observed for
three months after the challenge, and those horses without clinical
symptoms of EIA during this period were treated with a transient
immunosuppression, which was performed according to Tumas et al.
(1994) and Craigo et al. (2007).Viral RNA puriﬁcation and RT-PCR
Viral RNA was extracted from plasma samples using the QIAamp
Viral RNA Mini Kit (QIAGEN, German) after the virus pellets were
obtained by centrifugation at 100,000×g at 4 °C for 1 h. Puriﬁed viral
RNA was reverse-transcribed using the M-MLV Reverse Transcriptase
Kit (Invitrogen, USA) as speciﬁed by the manufacturer and the EIAV-
speciﬁc primer p8 (5′-TGACCCCATGATTCATTCCA-3′; nt 6980–6999 in
the EIAVLN40 genome). Subsequently, we ampliﬁed a speciﬁc fragment
from the plasma RNA samples that were obtained at different sampling
points using nested primers. The outer primers were as follows: p7 (5′-
CCACCAGAGTGTTGTGGAAAGGTG-3′; nt 5022–5045 in the EIAVLN40
genome); p8 (to amplify a fragment of approximately 1.9 kb). The inner
primers were as follows: p7-1 (5′-TTGTAAGGTTTGGTGTATGGG-3′; nt
5282–5302); p8-1 (5′-ATGGCAGCTATTATAGCAGA-3′; nt 6680–6699).
The fragment ampliﬁed by nested PCR was approximately 1.4 kb in
size, which was large enough to encompass the entire gp90 coding
region. The ampliﬁed PCR products were analyzed by 1% agarose gel
electrophoresis.
Cloning and sequencing
RT-PCR products were generated, gel-puriﬁed using the TaKaRa
Agarose Gel DNA Puriﬁcation Kit Ver. 2.0 (Takara, Japan), and cloned
individually into the pMD18-T vector (Takara). Individual clones were
screened by PCR. Positive E. coli colonies were then grown, and cloned
fragments in recombinant plasmids were sequenced by a commercial
gene-sequencing company (Shenggong, China).
Sequence analysis
The nucleotide and deduced amino acid sequences for each clone
were aligned using the ClustalW multiple sequence alignment
program available in the DNAStar software and edited using GeneDoc
software. Alignments were performed for the gp90 gene sequences
using the gp90 sequences of the GenBank-registered EIAV pathogenic
strain EIAVLN40 (accession number AF327877), the vaccine strain
EIAVFDDV12 (accession number AF327878), and the proviral derivative
EIAVFDDV3-8 (accession number GU385361.1) as the reference
sequences. All of the gp90 nucleotide sequences for the EIAVFDDV12
and EIAVFDDV3-8 species investigated herein were registered in
GenBank (accession numbers HQ242651 to HQ242710). The genetic
variation was calculated using the Kimura distance correction
program. The diversity levels were calculated using Dnsp 4.0 software.
Phylogenetic analyses of the gp90 sequences were conducted using
the neighbor-joining method. The tree was edited for presentation
using the Mega software, version 4.0.
Quantiﬁcation of the viral load
Plasma samples were analyzed for the viral RNA copy number per
milliliter of plasma according to a previously described quantitative
real-timemultiplex RT-PCR assay that is based on gag-speciﬁc primers
(Shen et al., 2006). The standard RNA curve was linear within a range
between 101molecules (lower limit) and 108molecules (upper limit).
RT activity assay
Viral reverse transcriptase (RT) was recovered from the cell
culture supernatants and quantiﬁed using an RT activity kit (Reverse
Transcriptase Assay, Colorimetric kit, Roche, Switzerland) as recom-
mended by the manufacturer. The detection protocol has been
described by Zheng et al. (1997). The RT activities are expressed as
optical density (OD) values, which were determined based on the
absorbance at 405 nm using a microplate reader (VERSAmax, USA).
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The standard agarose gel immune diffusion (AGID) diagnostic
assay kit (Harbin Veterinary Research Institute, China) was used to
evaluate the EIA sero-reactivity of serum samples from naïve horses
prior to vaccine inoculation.
The serum neutralization endpoints were determined according to
the following method. All of the sera were heat-inactivated at 56 °C
for 30 min to inactivate the virus and complement factors. Aliquots of
eMDM were plated in 96-well tissue culture plates at 1×105 cells/
well. The serum samples were serially diluted twice and incubated
with 1000 TCID50/ml of the indicator virus (EIAVDLV34) at 37 °C for
1 h. The serum/virus mixtures were added to microplates containing
eMDM and incubated for one day. Viruses in the culturemediumwere
removed by three washes with serum-free medium. Fresh MCM was
then added to the cultures, and the infected cells were incubated
further. Four days later, the growth of EIAV was monitored by
measuring the viral RT activity using a Roche RT detection kit. OD
values that were two-fold higher than those determined for the
negative control were considered to indicate a cytopathic effect (CPE).
The numbers of CPE wells were recorded, and the 50% reciprocal
neutralization titer for each serum sample was determined based on a
linear-regression analysis. A ten-fold dilution was considered the
cutoff value for a valid titer that provided 50% neutralization.Acknowledgments
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